|
所属 |
大学院医学系研究科（医学専攻等） 医学専攻 腫瘍制御医学系 腎泌尿器科学講座 |
|
生年 |
1974年 |
職務経歴（学内） 【 表示 ／ 非表示 】
-
2020年05月-継続中
秋田大学 大学院医学系研究科（医学専攻等） 医学専攻 腫瘍制御医学系 准教授
-
2017年01月-2020年04月
秋田大学 附属病院 血液浄化療法部 准教授
-
2011年01月-2016年12月
秋田大学 附属病院 泌尿器科 講師
研究等業績 【 表示 ／ 非表示 】
-
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.
Mizuki Kobayashi, Kazuyuki Numakura, Shingo Hatakeyama, Toshiya Ishida, Atsushi Koizumi, Kazuki Tadachi, Ryoma Igarashi, Koichiro Takayama, Yumina Muto, Yuya Sekine, Ryuta Sobu, Hajime Sasagawa, Hideo Akashi, Soki Kashima, Ryohei Yamamoto, Taketoshi Nara, Mitsuru Saito, Shintaro Narita, Chikara Ohyama, Tomonori Habuchi
International journal of clinical oncology 28 ( 11 ) 1530 - 1537 2023年11月
研究論文（学術雑誌）
BACKGROUND: Although nivolumab plus ipilimumab is the standard treatment for metastatic renal cell carcinoma (RCC), its efficacy and safety in older patients remain unclear. Therefore, this study aimed to assess the clinical outcomes of nivolumab plus ipilimumab for metastatic RCC in patients aged ≥ 75 years. METHODS: We enrolled 120 patients with metastatic RCC treated with nivolumab plus ipilimumab from August 2015 to January 2023. Objective response rates (ORRs) were compared between patients aged < 75 and ≥ 75 years. Progression-free survival (PFS), overall survival (OS), and adverse events were compared between the groups. Adverse events were evaluated according to the Response Evaluation Criteria in Solid Tumors 1.1. RESULTS: Among the patients, 57 and 63 were classified as intermediate and poor risk, respectively, and one could not be classified. The median follow-up duration after the initiation of treatment was 16 months. The patient characteristics between the groups, except for age, were not significantly different. Intergroup differences in ORR (42% vs. 40%; p = 0.818), PFS (HR: 0.820, 95% CI 0.455-1.479; p = 0.510), and median OS (HR: 1.492, 95% CI 0.737-3.020; p = 0.267) were not significant. The incidence of adverse events (50% vs. 67%; p = 0.111) and nivolumab plus ipilimumab discontinuation due to adverse events was not significantly different between the groups (14% vs. 13%; p = 0.877). CONCLUSIONS: The effectiveness of nivolumab plus ipilimumab was comparable between patients with metastatic RCC aged < 75 and those ≥ 75 years with respect to their ORRs, PFS, OS, and adverse event rates.
-
The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer.
Kazuyuki Numakura, Mizuki Kobayashi, Yumina Muto, Hiromi Sato, Yuya Sekine, Ryuta Sobu, Yu Aoyama, Yoshiko Takahashi, Syuhei Okada, Hajime Sasagawa, Shintaro Narita, Satoshi Kumagai, Yuki Wada, Naoko Mori, Tomonori Habuchi
Current oncology (Toronto, Ont.) 30 ( 9 ) 8092 - 8110 2023年09月
研究論文（学術雑誌）
A recent approach to radiotherapy for prostate cancer is the administration of high doses of radiation to the prostate while minimizing the risk of side effects. Thus, image-guided radiotherapy utilizes advanced imaging techniques and is a feasible strategy for increasing the radiation dose. New radioactive particles are another approach to achieving high doses and safe procedures. Prostate brachytherapy is currently considered as a combination therapy. Spacers are useful to protect adjacent organs, specifically the rectum, from excessive radiation exposure.
-
Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.
Kazuyuki Numakura, Yuya Sekine, Shingo Hatakeyama, Yumina Muto, Ryuta Sobu, Mizuki Kobayashi, Hajime Sasagawa, Soki Kashima, Ryohei Yamamto, Taketoshi Nara, Hideo Akashi, Ryuji Tabata, Satoshi Sato, Mitsuru Saito, Shintaro Narita, Chikara Ohyama, Tomonori Habuchi
Cancer medicine 12 ( 16 ) 16837 - 16845 2023年08月
研究論文（学術雑誌）
BACKGROUND: Nivolumab plus ipilimumab (NIVO+IPI) is the first-line treatment for patients with metastatic renal cell carcinoma (mRCC). Approximately 40% of patients achieve a durable response; however, 20% develop primary resistant disease (PRD) to NIVO+IPI, about which little is known in patients with mRCC. Therefore, this investigation aimed to evaluate the clinical implication of PRD in patients with mRCC to select better candidates in whom NIVO+IPI can be initiated as first-line therapy. METHODS: This multi-institutional retrospective cohort study used data collected between August 2015 and January 2023. In total, 120 patients with mRCC treated with NIVO+IPI were eligible. Associations between immune-related adverse events and progression-free survival, overall survival (OS), and objective response rate were analyzed. The relationship between other clinical factors and outcomes was also evaluated. RESULTS: The median observation period was 16 months (interquartile range, 5-27). The median age at NIVO+IPI initiation was 68 years in the male-dominant population (n = 86, 71.7%), and most patients had clear cell histology (n = 104, 86.7%). PRD was recorded in 26 (23.4%) of 111 investigated patients during NIVO+IPI therapy. Patients who experienced PRD showed worse OS (hazard ratio: 4.525, 95% confidence interval [CI]: 2.315-8.850, p < 0.001). Multivariable analysis showed that lymph node metastasis (LNM) (odds ratio: 4.274, 95% CI: 1.075-16.949, p = 0.039) was an independent risk factor for PRD. CONCLUSIONS: PRD was strongly correlated with worse survival rates. LNM was independently associated with PRD in patients with mRCC receiving NIVO+IPI as first-line therapy and might indicate that a candidate will not benefit from NIVO+IPI.
-
Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort.
Yoichiro Tohi, Ryou Ishikawa, Takuma Kato, Jimpei Miyakawa, Ryuji Matsumoto, Keiichiro Mori, Koji Mitsuzuka, Junichi Inokuchi, Masafumi Matsumura, Kenichiro Shiga, Hirohito Naito, Yasuo Kohjimoto, Norihiko Kawamura, Masaharu Inoue, Shusuke Akamatsu, Naoki Terada, Yoshiyuki Miyazawa, Shintaro Narita, Reiji Haba, Mikio Sugimoto
Japanese journal of clinical oncology 2023年07月
研究論文（学術雑誌）
BACKGROUND: In men undergoing upfront active surveillance, predictors of adverse pathology in radical prostatectomy specimens, including intraductal carcinoma of the prostate and cribriform patterns, remain unknown. Therefore, we aimed to examine whether adverse pathology in radical prostatectomy specimens could be predicted using preoperative patient characteristics. METHODS: We re-reviewed available radical prostatectomy specimens from 1035 men prospectively enrolled in the PRIAS-JAPAN cohort between January 2010 and September 2020. We defined adverse pathology on radical prostatectomy specimens as Gleason grade group ≥3, pT stage ≥3, pN positivity or the presence of intraductal carcinoma of the prostate or cribriform patterns. We also examined the predictive factors associated with adverse pathology. RESULTS: All men analyzed had Gleason grade group 1 specimens at active surveillance enrolment. The incidence of adverse pathologies was 48.9% (with intraductal carcinoma of the prostate or cribriform patterns, 33.6%; without them, 15.3%). The addition of intraductal carcinoma of the prostate or cribriform patterns to the definition of adverse pathology increased the incidence by 10.9%. Patients showing adverse pathology with intraductal carcinoma of the prostate or cribriform patterns had lower biochemical recurrence-free survival (log-rank P = 0.0166). Increasing age at active surveillance enrolment and before radical prostatectomy was the only predictive factor for adverse pathology (odds ratio: 1.1, 95% confidence interval: 1.02-1.19, P = 0.0178; odds ratio: 1.12, 95% confidence interval: 1.02-1.22, P = 0.0126). CONCLUSIONS: Increasing age could be a predictive factor for adverse pathology. Our findings suggest that older men could potentially derive advantages from adhering to the examination schedule in active surveillance.
-
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Takafumi Yanagisawa, Kenichi Hata, Shintaro Narita, Shingo Hatakeyama, Keiichiro Mori, Yuji Yata, Takayuki Sano, Takashi Otsuka, Shuhei Hara, Keiichiro Miyajima, Yuki Enei, Wataru Fukuokaya, Minoru Nakazono, Akihiro Matsukawa, Jun Miki, Tomonori Habuchi, Chikara Ohyama, Shahrokh F Shariat, Takahiro Kimura
The Prostate 83 ( 6 ) 563 - 571 2023年05月
研究論文（学術雑誌）
PURPOSE: We aimed to assess the oncologic efficacy of combining docetaxel (DOC) versus abiraterone (ABI) with androgen deprivation therapy (ADT) in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC), with a focus on the efficacy of sequential therapy, in a real-world clinical practice setting. METHODS: The records of 336 patients who harbored de novo high-risk mHSPC, based on the LATITUDE criteria, and had received ADT with either DOC (n = 109) or ABI (n = 227) were retrospectively analyzed. Overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), including time to castration-resistant prostate cancer (CRPC), time to 2nd-line progression (PFS2), and 2nd- and 3rd-line PFS, were compared. We used one-to-two propensity score matching to minimize the confounders. The differential efficacy of 2nd-line therapy based on agents in each arm was evaluated using the unmatched cohort as an additional interest. RESULTS: After propensity score matching, 86 patients treated with DOC + ADT and 172 with ABI + ADT were available for analyses. The 3-year OS and CSS for DOC versus ABI were 76.2% versus 75.1% (p = 0.8) and 78.2% versus 78.6% (p = 1), respectively. There was no difference in the median PFS2 (49 vs. 43 months, p = 0.39), while the median time to CRPC in patients treated with ABI was significantly longer compared to those treated with DOC (42 vs. 22 months; p = 0.006). The median 2nd-line PFS (14 vs. 4 months, p < 0.001) and 3rd-line PFS (4 vs. 2 months, p = 0.012) were significantly better in the DOC group than in the ABI group. Among the unmatched cohort, after ABI for mHSPC, the median 2nd-line PFS did not differ between the patients treated with DOC and those treated with enzalutamide as 2nd-line therapy (both 3 months, p = 0.8). CONCLUSIONS: ADT with DOC or ABI has comparable oncologic outcomes in terms of OS, CSS, and PFS2 in patients with de novo high-risk mHSPC. Compared to DOC, ABI resulted in longer time to CRPC but worse 2nd and 3rd-line PFS. Further studies are needed to clarify the optimal sequence of therapy in the upfront intensive treatment era.
-
ニボルマブ・イピリムマブ併用療法に対して治療不応性を示す転移性腎細胞癌患者の特徴
沼倉 一幸, 畠山 真吾, 武藤 弓奈, 関根 悠哉, 蘇武 竜太, 小林 瑞貴, 笹川 甫, 嘉島 相輝, 山本 竜平, 奈良 健平, 齋藤 満, 成田 伸太郎, 大山 力, 羽渕 友則
腎癌研究会会報 ( (一社)腎癌研究会 ) ( 53 ) 49 - 49 2023年07月
-
当科におけるペムブロリズマブ・レンバチニブ併用療法の初期治療経験
関根 悠哉, 沼倉 一幸, 小林 瑞貴, 山本 竜平, 奈良 健平, 齋藤 満, 成田 伸太郎, 羽渕 友則
腎癌研究会会報 ( (一社)腎癌研究会 ) ( 53 ) 54 - 54 2023年07月
-
転移性腎細胞癌に対するニボルマブ+イピリムマブ併用療法のirAEと治療効果の関連についての検討
蘇武 竜太, 沼倉 一幸, 畠山 真吾, 関根 悠哉, 武藤 弓奈, 小林 瑞貴, 嘉島 相輝, 山本 竜平, 小泉 淳, 奈良 健平, 齋藤 満, 成田 伸太郎, 大山 力, 羽渕 友則
腎癌研究会会報 ( (一社)腎癌研究会 ) ( 53 ) 87 - 87 2023年07月
-
BRAF V600E変異は副腎腫瘍からのコルチゾール産生を亢進する(BRAF V600E mutation promoted excess of cortisol secretion in adrenal cortical adenoma)
沼倉 一幸, 武藤 弓奈, 杉山 志子, 小林 瑞貴, 関根 悠哉, 嘉島 相輝, 山本 竜平, 奈良 健平, 黄 明国, 齋藤 満, 成田 伸太郎, 西本 紘嗣郎, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 110回 AOP08 - 03 2023年04月
-
船越 佑大, 嘉島 相輝, 関根 悠哉, 小林 瑞貴, 山本 竜平, 奈良 健平, 沼倉 一幸, 齋藤 満, 成田 伸太郎, 羽渕 友則, 南條 博
泌尿器外科 ( 医学図書出版(株) ) 36 ( 4 ) 357 - 357 2023年04月
◆原著論文【 表示 ／ 非表示 】
◆その他【 表示 ／ 非表示 】
学術関係受賞 【 表示 ／ 非表示 】
-
Best Presentation Award of the ACRLS 2022
2022年12月 Asian-Pacific Congress of Robotic Laparoscopic Surgery Best Presentation Award of the ACRLS 2022
受賞者： Shintaro Narita -
優秀演題賞
2022年10月 第60回日本癌治療学会学術集会 優秀演題賞
受賞者： 成田伸太郎
科研費（文科省・学振）獲得実績 【 表示 ／ 非表示 】
-
免疫チェックポイント阻害薬の治療有効性・抵抗性の要因評価～宿主腫瘍HLA環境解析
基盤研究(C)
研究期間: 2021年04月 - 2025年03月 代表者: 藤山 信弘, 成田 伸太郎, 細道 一善, 嘉島 相輝
-
ファーマコゲノミクスとトランスクリプトミクスによる腎癌薬物療法の新治療体系の確立
基盤研究(C)
研究期間: 2015年04月 - 2018年03月 代表者: 土谷 順彦, 成田 伸太郎, 黄 明国, 藤山 信弘
-
長鎖脂肪酸による前立腺癌進展の機序解明－パルミチン酸とＭＩＣ－１の関連－
基盤研究(C)
研究期間: 2012年04月 - 2015年03月 代表者: 黄 明国, 成田 伸太郎, 土谷 順彦
-
ＳＮＰアレイを用いた前立腺癌の進展関連分子の同定とリスク予測モデルの構築
基盤研究(C)
研究期間: 2012年04月 - 2015年03月 代表者: 土谷 順彦, 羽渕 友則, 成田 伸太郎
-
希少腎細胞癌の分子病態解析と治療標的分子候補の同定
挑戦的萌芽研究
研究期間: 2011年 - 2013年 代表者: 羽渕 友則, 大山 力, 三股 浩光, 成田 伸太郎, 南條 博
学会等発表 【 表示 ／ 非表示 】
-
増刊号特集 泌尿器内視鏡最新手術 副腎・腎・後腹膜の手術 ロボット支援腹腔鏡下腎尿管全摘除術[右・左]
齋藤 満, 成田 伸太郎, 羽渕 友則
臨床泌尿器科 2023年04月 - 2023年04月 株式会社医学書院
-
Sekine Y.
Japanese journal of clinical oncology 2022年12月 - 2022年12月 Japanese journal of clinical oncology
-
特集 限局性前立腺癌診療バイブル-このへんでキッチリと前立腺癌診療の"あたりまえ"を整理しよう! 〈高齢者・その他〉 高齢者限局性前立腺癌治療
成田 伸太郎
臨床泌尿器科 2022年10月 - 2022年10月 株式会社医学書院
-
Nagumo Y.
International Journal of Urology 2022年05月 - 2022年05月 International Journal of Urology
-
Ozaki K.
World Journal of Urology 2022年 - 2022年 World Journal of Urology